当前位置: X-MOL 学术EFORT Open Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials.
EFORT Open Reviews ( IF 4.3 ) Pub Date : 2022-07-05 , DOI: 10.1530/eor-21-0103
Di Zhao 1, 2 , Ling-Feng Zeng 2, 3 , Gui-Hong Liang 2, 3 , Jian-Ke Pan 3 , Ming-Hui Luo 3 , Yan-Hong Han 3 , Jun Liu 2, 4, 5 , Wei-Yi Yang 3
Affiliation  

Considering the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for treating osteoarthritis (OA), development of drugs that are more effective and better tolerated than existing treatments is urgently needed. This systematic review aimed to evaluate the efficacy and safety of anti-nerve growth factor (NGF) monoclonal antibodies vs active comparator therapy, such as NSAIDs and oxycodone, in treating hip or knee OA.

中文翻译:


抗神经生长因子单克隆抗体治疗是否有可能取代非甾体抗炎药和阿片类药物治疗髋关节或膝骨关节炎?随机对照试验的系统评价。



考虑到非甾体类抗炎药(NSAID)和阿片类药物治疗骨关节炎(OA)的副作用,迫切需要开发比现有治疗方法更有效、耐受性更好的药物。本系统综述旨在评估抗神经生长因子 (NGF) 单克隆抗体与非甾体抗炎药和羟考酮等主动比较疗法在治疗髋部或膝部 OA 方面的疗效和安全性。
更新日期:2022-07-05
down
wechat
bug